KPV
A three-amino-acid fragment (Lys-Pro-Val) studied for inflammatory signaling. The published work is in cells and mouse models of colitis, and we found no human trials.
How it is offered
Priced With Your Plan
Pricing
Your clinician sets the plan. Pricing is shown before you authorize any charge.
KPV requires a written prescription from a licensed clinician and is prepared by a licensed pharmacy for an individual patient. Compounded medications are not FDA-approved or evaluated for safety, effectiveness or quality. Evidence standards.
Start Your Assessment →What Is KPV?
KPV is the final three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone with anti-inflammatory activity. Laboratory work asks whether the fragment keeps that activity.
Two 2008 studies found KPV reduced inflammatory signaling in human cell lines and reduced colitis in mice, including when given orally. That is early, mechanistic evidence. It has not been tested in people.
Good to Know
- Prescribed only after a clinician reviews your history.
- Dose and course are set by your clinician, not by you.
- Results vary, and we do not promise outcomes.
Who It Is For
Eligibility
Competitive Athletes
Many peptides are prohibited in sport, or fall under rules that change. A prescription does not establish sporting eligibility, so we ask about anti-doping rules before presenting any option.
Often a Good Fit If
- ✓A persistent inflammatory complaint that has already been evaluated by a clinician
- ✓Comfortable with no human trial data
- ✓Willing to complete a baseline visit and a defined course
- ✓Open to stopping if there is no measurable or subjective benefit
Not Prescribed If
- —Pregnancy, breastfeeding, or actively trying to conceive
- —Active or recent cancer diagnosis, or a history your clinician judges to carry risk
- —Expecting a guaranteed or fast outcome rather than a considered trial
- —A new or undiagnosed gastrointestinal or inflammatory symptom that has not been evaluated
- —Prior serious hypersensitivity to KPV or its excipients
Read Before You Decide
Key Risks, Stated Plainly
There is no human safety record for KPV. The mouse studies were designed to test efficacy, not to establish safety in people. KPV sits on FDA's Category 2 safety-risk page. Because anti-inflammatory signaling is complex, we do not treat it as a way to avoid evaluating an inflammatory condition.
Contact care the same day for
Blood in the stool, severe abdominal pain, fever, signs of allergic reaction, or any new or unexplained symptom during a course.
What Is Measured
Symptom Baseline
A baseline you rate at the start, then again at each check-in.
Relevant Labs
Inflammatory markers where your clinician judges them useful.
Tolerance
Injection sites and any new symptoms, reviewed early.
Course Endpoint
A scheduled reassessment against your original goal.
A Clearer Path Forward
How Clinicians Review Your Response
You and Your Clinician Look at the Same Data
Symptoms you report, laboratory results and, if you connect one, wearable trends are reviewed together before any change.
A Physician-Led Review Every 90 Days
Included in your monthly price. Your clinician decides whether to continue, adjust the dose, change course or stop.
Clinical Judgment Decides
Measurements inform the decision. They do not make it, and no dashboard changes your dose on its own.
Your Care Sequence
01
Questionnaire
Share your goals, history and any sport or work rules in about ten minutes. No card required.
02
Video Visit
Your clinician reviews your history and medications, explains the evidence plainly, and decides whether this fits you.
03
Delivery
If prescribed, medication ships from a licensed pharmacy with supplies and written instructions.
04
Reassessment
A scheduled review decides whether to stop, extend or change course. Courses are not renewed by default.
Common Questions About KPV
Has KPV Been Tested in People?+
We found no published human trials. The key studies are in human cell lines and mouse models of colitis.
What Did the Mouse Studies Show?+
In 2008 studies, KPV reduced inflammatory signaling in human intestinal and T cells and reduced the incidence of colitis in mice, including with oral administration. These are laboratory results.
Is KPV FDA-Approved?+
No. It is not an FDA-approved drug, and it appears on FDA's Category 2 safety-risk page.
Is It Available Through SOVRYN?+
KPV is prescribed only after a clinician reviews your history and decides it fits. Start with the assessment and your clinician will tell you what is and is not appropriate.
Still unsure? Message the care team before you join. No account needed.
Published Research
What the Published Science Shows
0
Human trials of KPV that we found.
2 + 2
Mouse models of intestinal inflammation tested across two 2008 papers.
Nanomolar
Concentrations at which KPV reduced inflammatory signaling in human cell lines.
Figures come from the cited trials and reviews. They describe published research, not a forecast for any one person, and not a study of compounded formulations.
The Mechanism
The Proposed Mechanism
PepT1 Uptake
KPV is transported into intestinal and immune cells by PepT1, a peptide transporter increased in inflamed gut.
NF-kB Signaling
In cells, nanomolar KPV reduced NF-kB and MAP-kinase signaling.
Colitis Models
In mice, KPV reduced inflammatory cytokines and the incidence of colitis.
For Readers Who Want More
Deeper Evidence
What We Can and Cannot Tell YouEvidence and regulatory status+
What the Evidence Supports
Consistent findings in human cell lines and two mouse models that KPV reduces NF-kB and MAP-kinase signaling and inflammatory cytokines, with transport into cells via the PepT1 transporter.
What It Does Not (Yet)
No human trials, no established dose or safety in people, and no evidence that it helps any inflammatory condition in humans.
Badge definitions and FDA category sourcing are on the Science page.
Illustrative Course StructureFinal dose set by your clinician+
Illustrative only and not a prescription. Dose, timing and length are set by your clinician and the compounding pharmacy.
| Phase | Approach | Duration | What We Watch |
|---|---|---|---|
| Baseline | Visit, labs where indicated | Before starting | Symptoms, relevant labs |
| Course | Clinician-set dose, held at the tolerated level | Defined by your clinician | Tolerance, response |
| Reassessment | Extend, stop or change course | At the scheduled review | Whether the goal was met |
Selected Studies
Dalmasso et al., Gastroenterology, 2008 (PMID 18061177)
In human cell lines and in two mouse models of colitis, KPV reduced inflammatory signaling and the incidence of colitis. These were laboratory and animal experiments, not human trials.
Read the Source ↗Kannengiesser et al., Inflammatory Bowel Diseases, 2008
KPV, the C-terminal tripeptide of alpha-MSH, showed anti-inflammatory activity in two mouse models of intestinal inflammation (DSS colitis and CD45RB-high transfer colitis).
Read the Source ↗Renke and Chinellato, International Journal of Molecular Sciences, 2026 (review of 106 articles)
Reviewed the effects, safety and regulatory status of prominent therapeutic peptides, including unapproved ones, and concluded that further studies are needed before most new peptides can be used safely in humans.
Read the Source ↗Often Considered Together
Paired With
Start Your Assessment for Recovery Options
Ten minutes, no card, reviewed by a clinician.